FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136162734> ?p ?o ?g. }

• W3136162734 endingPage "1938" @default.
• W3136162734 startingPage "1937" @default.
• W3136162734 abstract "In an article previously published in Cancer, Cattaneo et al1 analyzed a cohort of patients with coronavirus disease 2019 (COVID-19) and hematological malignancies in March 2020, and they highlighted that subjects with chronic myeloid leukemia (CML) had a lower than expected frequency of COVID-19. The authors linked this observation to the lower level of immunodeficiency seen in CML and to a potential protective role of tyrosine kinase inhibitors (TKIs) based on the possible antiviral activity of these drugs. However, they reported a mortality rate 30 days after the documentation of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection of 50% in the group of patients with chronic myeloproliferative malignancies, which included patients with CML (78% of these patients were treated with TKIs). As the authors insightfully pointed out in their article, imatinib (the main TKI for CML treatment) has shown antiviral effects against other betacoronaviruses in in vitro studies, probably by preventing virus entry into host cells via interference with the fusion between viral and cellular membranes.2, 3 Regarding SARS-CoV-2, there are conflicting data about the antiviral potential of this drug: although significant suppression of viral replication in Vero E6 cells has been described,4 no potent effect over the virus lifecycle in Caco-2 cell cultures has been recently reported with the standard dosage of imatinib (400-800 mg/d).5 Furthermore, imatinib might exert its potential protective role in COVID-19 through its immunomodulatory properties.6 Murine models of sepsis and acute lung injury have suggested that this drug has a beneficial effect by reducing pulmonary edema, preventing histological damage, and improving endothelial barrier integrity, probably by attenuating the release of proinflammatory cytokines, including interleukin 6 and tumor necrosis factor α.7, 8 This cytokine downregulation has also been observed in patients with CML9 and seems to be mediated by the inhibition of transcription factor NF-κB according to previous evidence from animal and human cell studies.10 This is particularly interesting because the NF-κB pathway has been pointed out as one of the main inflammatory signaling cascades leading to the pulmonary damage observed in severe COVID-19.11 In this regard, both a lower incidence and a lower severity of this condition have been consistently reported in subjects with CML.12-14 In fact, Passamonti et al15 have recently found that all patients with CML under TKI treatment in their Italian multicenter cohort of hematological patients with a SARS-CoV-2 infection were alive at the end of follow-up. In conclusion, we consider that the positive outcomes of TKI-treated CML patients with COVID-19, including a lower frequency of SARS-CoV-2 infection and a higher survival rate, strengthen the hypothesis that these drugs might be beneficial in the treatment of this disease. Hence, we believe that a more detailed description by Cattaneo et al1 about deceased subjects with CML under TKI therapy in their study would be valuable. Finally, further clinical research should be encouraged to assess the effectiveness of imatinib and other related TKIs in COVID-19. No specific funding was disclosed. Miguel Ángel Canales-Albendea declares consulting fees from Novartis. David Bernal-Bello is the principal investigator of a nonsponsored randomized trial investigating the therapeutic role of imatinib and baricitinib in patients with coronavirus disease 2019 (NCT04346147); Alejandro Morales-Ortega, Begoña Frutos-Pérez, Beatriz Jaenes-Barrios, and Ana Isabel Farfán-Sedano are subinvestigators of this project. The other author made no disclosures." @default.
• W3136162734 created "2021-03-29" @default.
• W3136162734 creator A5012501276 @default.
• W3136162734 creator A5032154924 @default.
• W3136162734 creator A5032871169 @default.
• W3136162734 creator A5058170926 @default.
• W3136162734 creator A5059352840 @default.
• W3136162734 creator A5061130412 @default.
• W3136162734 creator A5069405406 @default.
• W3136162734 date "2021-03-15" @default.
• W3136162734 modified "2023-09-24" @default.
• W3136162734 title "COVID‐19 in patients with hematological malignancies: Considering the role of tyrosine kinase inhibitors" @default.
• W3136162734 cites W1982321591 @default.
• W3136162734 cites W2171847267 @default.
• W3136162734 cites W2183951280 @default.
• W3136162734 cites W2186582982 @default.
• W3136162734 cites W2520543291 @default.
• W3136162734 cites W2789227767 @default.
• W3136162734 cites W3022840916 @default.
• W3136162734 cites W3023650684 @default.
• W3136162734 cites W3025235397 @default.
• W3136162734 cites W3036751670 @default.
• W3136162734 cites W3048434629 @default.
• W3136162734 cites W3050026397 @default.
• W3136162734 cites W3085572519 @default.
• W3136162734 cites W3091228967 @default.
• W3136162734 cites W3092343514 @default.
• W3136162734 doi "https://doi.org/10.1002/cncr.33432" @default.
• W3136162734 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8250378" @default.
• W3136162734 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33721325" @default.
• W3136162734 hasPublicationYear "2021" @default.
• W3136162734 type Work @default.
• W3136162734 sameAs 3136162734 @default.
• W3136162734 citedByCount "2" @default.
• W3136162734 countsByYear W31361627342022 @default.
• W3136162734 crossrefType "journal-article" @default.
• W3136162734 hasAuthorship W3136162734A5012501276 @default.
• W3136162734 hasAuthorship W3136162734A5032154924 @default.
• W3136162734 hasAuthorship W3136162734A5032871169 @default.
• W3136162734 hasAuthorship W3136162734A5058170926 @default.
• W3136162734 hasAuthorship W3136162734A5059352840 @default.
• W3136162734 hasAuthorship W3136162734A5061130412 @default.
• W3136162734 hasAuthorship W3136162734A5069405406 @default.
• W3136162734 hasBestOaLocation W31361627341 @default.
• W3136162734 hasConcept C126322002 @default.
• W3136162734 hasConcept C159047783 @default.
• W3136162734 hasConcept C170493617 @default.
• W3136162734 hasConcept C203014093 @default.
• W3136162734 hasConcept C2776232967 @default.
• W3136162734 hasConcept C2776256026 @default.
• W3136162734 hasConcept C2777583451 @default.
• W3136162734 hasConcept C2777648638 @default.
• W3136162734 hasConcept C2778729363 @default.
• W3136162734 hasConcept C2779134260 @default.
• W3136162734 hasConcept C2779422266 @default.
• W3136162734 hasConcept C3008058167 @default.
• W3136162734 hasConcept C3019892230 @default.
• W3136162734 hasConcept C42362537 @default.
• W3136162734 hasConcept C524204448 @default.
• W3136162734 hasConcept C71924100 @default.
• W3136162734 hasConceptScore W3136162734C126322002 @default.
• W3136162734 hasConceptScore W3136162734C159047783 @default.
• W3136162734 hasConceptScore W3136162734C170493617 @default.
• W3136162734 hasConceptScore W3136162734C203014093 @default.
• W3136162734 hasConceptScore W3136162734C2776232967 @default.
• W3136162734 hasConceptScore W3136162734C2776256026 @default.
• W3136162734 hasConceptScore W3136162734C2777583451 @default.
• W3136162734 hasConceptScore W3136162734C2777648638 @default.
• W3136162734 hasConceptScore W3136162734C2778729363 @default.
• W3136162734 hasConceptScore W3136162734C2779134260 @default.
• W3136162734 hasConceptScore W3136162734C2779422266 @default.
• W3136162734 hasConceptScore W3136162734C3008058167 @default.
• W3136162734 hasConceptScore W3136162734C3019892230 @default.
• W3136162734 hasConceptScore W3136162734C42362537 @default.
• W3136162734 hasConceptScore W3136162734C524204448 @default.
• W3136162734 hasConceptScore W3136162734C71924100 @default.
• W3136162734 hasIssue "11" @default.
• W3136162734 hasLocation W31361627341 @default.
• W3136162734 hasLocation W31361627342 @default.
• W3136162734 hasOpenAccess W3136162734 @default.
• W3136162734 hasPrimaryLocation W31361627341 @default.
• W3136162734 hasRelatedWork W1984160018 @default.
• W3136162734 hasRelatedWork W2035155744 @default.
• W3136162734 hasRelatedWork W2120077570 @default.
• W3136162734 hasRelatedWork W2182796777 @default.
• W3136162734 hasRelatedWork W2273178174 @default.
• W3136162734 hasRelatedWork W2378937667 @default.
• W3136162734 hasRelatedWork W2563198120 @default.
• W3136162734 hasRelatedWork W4230849756 @default.
• W3136162734 hasRelatedWork W47702910 @default.
• W3136162734 hasRelatedWork W2028346583 @default.
• W3136162734 hasVolume "127" @default.
• W3136162734 isParatext "false" @default.
• W3136162734 isRetracted "false" @default.
• W3136162734 magId "3136162734" @default.
• W3136162734 workType "article" @default.